Health Condition 1: null- Patients with Type 2 Diabetes Mellitus Health Condition 2: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: There are no treatment groups for this study. The patient population for this study will consist of patients with type 2 diabetes mellitus being started on dulaglutide as per the approv
Sponsors
Eli Lilly and Company India Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Provide written consent (consent to release information) for this study, 2.diagnosed with type 2 diabetes mellitus 3.have a baseline HbA1c =10% (as per the lab report from the last 60 days) 4.have never been treated by dulaglutide 5.is determined by the investigator before enrollment that the patient is appropriate to be treated with dulaglutide
Exclusion criteria
Exclusion criteria: 1.Are investigator site personnel directly affiliated with the study, and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted 2.Are employed by Lilly (i.e. employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly employees may participate in Lilly-sponsored or Lilly-managed clinical trials, but are not permitted to participate at a Lilly facility. Immediate family is defined above. 3.Are simultaneously participating in a clinical trial that includes a treatment intervention and/or dulaglutide 4.Have any contraindication to dulaglutide 5.Are pregnant or lactating mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of patientTimepoint: Safety assessment will be done at the end of 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Complaint HandlingTimepoint: Product Complaint assessment will be done at the end of 24 weeks | — |
Countries
India
Contacts
Public ContactDr Rajeev Sharan Shrivastava
Eli Lilly and Company (India) Pvt. Ltd.
Outcome results
None listed